Orgenesis Inc Revenue Growth Rates (ORGS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Orgenesis Inc   (ORGS)
 

ORGS's Revenue Growth by Quarter and Year

Orgenesis Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ORGS Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 0.30
3rd Quarter September 0.35
2nd Quarter June 0.25
1st Quarter March 0.14
FY 1.04

ORGSs Annual Revenue
Orgenesis Inc 's Revenue in the fiscal year 2024 $ 0.11 millions
Orgenesis Inc 's Revenue in the fiscal year 2023 $ 0.28 millions
Orgenesis Inc 's Revenue in the fiscal year 2022 $ 36.03 millions
Orgenesis Inc 's Revenue in the fiscal year 2021 $ 35.50 millions
Orgenesis Inc 's Revenue in the fiscal year 2020 $ 7.65 millions




ORGS Revenue fourth quarter 2024 Y/Y Growth Comment
Orgenesis Inc reported Revenue surge of 77.06% year on year in the fourth quarter 2024, to $ 0.30 millions, this is lower than Orgenesis Inc 's recent average Revenue surge of 13292.68%.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 46 other companies have achieved higher Revenue growth. While Orgenesis Inc ' s Revenue jump of 77.06% ranks overall at the positon no. 365 in the fourth quarter 2024.


ORGS Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December 77.06 % -98.75 % 97.68 % 199.57 %
3rd Quarter September 218.18 % -98.62 % -7.95 % 401.73 %
2nd Quarter June 127.27 % -98.47 % -31.75 % 502.86 %
1st Quarter March 0 % -98.06 % -23.22 % 399.47 %
FY   96.42 % -98.53 % 1.44 % -

Financial Statements
Orgenesis Inc 's fourth quarter 2024 Revenue $ 0.30 millions ORGS's Income Statement
Orgenesis Inc 's fourth quarter 2023 Revenue $ 0.17 millions Quarterly ORGS's Income Statement


ORGS Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December -14 % 54.55 % 70.46 % -20.62 %
3rd Quarter September 40 % 0 % 10.97 % -17.73 %
2nd Quarter June 78.57 % -21.43 % -0.14 % 12.35 %
1st Quarter March -17.65 % -98.97 % 4.64 % 308.26 %
FY (Year on Year)   96.42 % -98.53 % 1.44 % -


Back to ORGS Growth rate Comparisons >> Back to ORGS Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #90
Overall #365

Revenue Y/Y Growth Statistics
High Average Low
202903.53 % 13292.68 % -99.86 %
(Aug 31 2017)   (Dec 31 2023)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #47
Healthcare Sector #90
Overall #365
Revenue Y/Y Growth Statistics
High Average Low
202903.53 % 13292.68 % -99.86 %
(Aug 31 2017)   (Dec 31 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Orgenesis Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
345627.37 % 9604.83 % -99.88 %
(Nov 30 2016)  


ORGS's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2024 Orgenesis Inc disclosed drop in Revenue from the third quarter by -14% to $ 0.30 millions, from $ 0.35 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2024 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 176 other companies have achieved higher Revenue quarter on quarter growth. While Orgenesis Inc 's Revenue growth quarter on quarter, overall rank is 3276.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #177
Healthcare Sector #492
Overall #3276
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #177
Healthcare Sector #492
Overall #3276
Revenue Q/Q Growth Statistics
High Average Low
345627.37 % 9604.83 % -99.88 %
(Nov 30 2016)  


ORGS's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2024 Orgenesis Inc disclosed drop in Revenue from the third quarter by -14% to $ 0.30 millions, from $ 0.35 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2024 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 176 other companies have achieved higher Revenue quarter on quarter growth. While Orgenesis Inc 's Revenue growth quarter on quarter, overall rank is 3276.


Orgenesis Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)
Cumulative Revenue 12 Months Ending $ 1.04 $ 0.90 $ 0.66 $ 0.53 $ 0.53
Y / Y Revenue Growth (TTM) 95.28 % -93.57 % -96.97 % -98.17 % -98.53 %
Year on Year Revenue Growth Overall Ranking # 4034 # 3424 # 0 # 2473 # 0
Seqeuential Revenue Change (TTM) 15.13 % 35.8 % 25.14 % -0.19 % -96.21 %
Seq. Revenue Growth (TTM) Overall Ranking # 4028 # 3307 # 0 # 2685 # 0


Cumulative Revenue growth Comment
Orgenesis Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 95.28% year on year, to $ 1 millions if the fiscal year would have ended in Dec 31 2024.
Orgenesis Inc 's trailing twelve months Revenue growth was higher than company's average 59.37% and higher than -93.57% growth in Sep 30 2024.
But from twelve months ended Sep 30 2024 rise was beneth at 15.13 % from $0.9 millions achieved in the period from Sep 30 2024 to Dec 31 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at59.37%.
The momentum is even more impressive from twelve months ended Sep 30 2024 exhibited at 15.13 % increase from $0.9 millions in the period from Sep 30 2024 to Dec 31 2023.

In the Healthcare sector 561 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3424 to 4034.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 212
Healthcare Sector # 562
Overall # 4034

Revenue TTM Y/Y Growth Statistics
High Average Low
972.5 %
 59.37 %
-98.28 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 212
Sector # 561
S&P 500 # 4028
Cumulative Revenue growth Comment
Orgenesis Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 95.28% year on year, to $ 1 millions if the fiscal year would have ended in Dec 31 2024.
Orgenesis Inc 's trailing twelve months Revenue growth was higher than company's average 59.37% and higher than -93.57% growth in Sep 30 2024.
But from twelve months ended Sep 30 2024 rise was beneth at 15.13 % from $0.9 millions achieved in the period from Sep 30 2024 to Dec 31 2023.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at59.37%.
The momentum is even more impressive from twelve months ended Sep 30 2024 exhibited at 15.13 % increase from $0.9 millions in the period from Sep 30 2024 to Dec 31 2023.

In the Healthcare sector 561 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3424 to 4034.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 212
Healthcare Sector # 562
Overall # 4034

Revenue TTM Y/Y Growth Statistics
High Average Low
972.5 %
59.37 %
-98.28 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 212
Sector # 561
S&P 500 # 4028




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ORGS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2024
Omniab Inc 124.06%$ 124.056 millions
Earth Science Tech Inc 117.75%$ 117.746 millions
Krystal Biotech Inc 116.26%$ 116.264 millions
Esperion Therapeutics Inc 114.30%$ 114.304 millions
Marker Therapeutics inc 113.13%$ 113.128 millions
Myomo Inc 111.46%$ 111.460 millions
Biorestorative Therapies Inc 106.19%$ 106.190 millions
Beyond Air Inc 100.77%$ 100.767 millions
Nuo Therapeutics Inc 100.43%$ 100.427 millions
First Choice Healthcare Solutions Inc 99.80%$ 99.800 millions
Scpharmaceuticals Inc 99.31%$ 99.311 millions
Qhslab Inc 98.71%$ 98.712 millions
Evoke Pharma Inc 97.40%$ 97.398 millions
Absci Corp96.75%$ 96.746 millions
Hims and Hers Health Inc 94.39%$ 94.395 millions
Dariohealth Corp 93.72%$ 93.718 millions
60 Degrees Pharmaceuticals Inc 92.20%$ 92.204 millions
Blueprint Medicines Corporation88.19%$ 88.190 millions
Ac Immune Sa88.19%$ 88.190 millions
Agilon Health Inc 86.69%$ 86.693 millions
Regen Biopharma Inc 86.68%$ 86.678 millions
Genfit S a 85.82%$ 85.821 millions
Harrow Inc 83.83%$ 83.829 millions
Zymeworks Inc 83.33%$ 83.333 millions
Orgenesis Inc 82.42%$ 82.424 millions
Macrogenics Inc 80.53%$ 80.532 millions
Septerna Inc 79.66%$ 79.661 millions
Avricore Health Inc 79.01%$ 79.014 millions
Ideaya Biosciences Inc 78.43%$ 78.435 millions
Argenx Se78.05%$ 78.053 millions


About Orgenesis Inc Revenue Growth Rates (ORGS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Orgenesis Inc (CIK 1460602).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-012845
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Orgenesis Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.